SABS
SAB Biotherapeutics Inc
NASDAQ: SABS · HEALTHCARE · BIOTECHNOLOGY
$3.72
+3.27% today
Updated 2026-06-04
Market cap
$253.86M
P/E ratio
—
P/S ratio
2.96x
EPS (TTM)
$-0.58
Dividend yield
—
52W range
$2 – $5
Volume
0.7M
SAB Biotherapeutics Inc (SABS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-0.32%
ROA
-25.40%
Debt/equity
0.03x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $3.44M | $-8.99M | 100.00% | -252.00% | -261.07% |
| 2020 | $55.24M | $20.12M | 100.00% | 37.22% | 36.42% |
| 2021 | $60.88M | $-17.14M | 97.28% | -22.00% | -28.16% |
| 2022 | $23.90M | $-18.74M | 86.23% | -120.98% | -78.40% |
| 2023 | $2.24M | $-42.19M | -67.26% | -1,700.54% | -1,884.50% |
| 2024 | $1.32M | $-34.11M | -262.41% | -3,244.87% | -2,579.03% |
| 2025 | $0.00 | $13.27M | — | — | — |
Frequently asked questions
What is SAB Biotherapeutics Inc's revenue?
SAB Biotherapeutics Inc's trailing twelve-month revenue is $114700.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does SABS generate?
SABS produced $-45.71M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is SABS's balance sheet healthy?
SABS holds $10.50M in cash and equivalents against — in long-term debt, on $151.49M of shareholder equity. That debt is best read against the cash flow the business throws off each year.